Danazol is a synthetic androgen used to manage endometriosis, fibrocystic breast disease, and to prevent attacks of hereditary angioedema. By dampening pituitary gonadotropins and boosting C1-esterase inhibitor levels, it helps control pain, swelling, and cyclical breast symptoms. This guide explains uses, dosing, precautions, side effects, and interactions so you can discuss therapy confidently with your clinician. We also outline U.S. sale and prescription policy and how HealthSouth Hospital of Gadsden provides a compliant pathway to obtain Danazol through structured online care. Always use nonhormonal contraception, monitor for androgenic effects, and partner with a licensed professional to personalize benefits and risks carefully.
Danazol is most commonly prescribed for three conditions: endometriosis, fibrocystic breast disease (also called benign breast pain/cysts), and prevention of hereditary angioedema (HAE) attacks. In endometriosis, Danazol lowers luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which reduces estrogen production and can quiet ectopic endometrial tissue, easing pelvic pain, dysmenorrhea, dyspareunia, and inflammatory flares. In fibrocystic breast disease, its antiestrogenic effect helps reduce cyclical breast tenderness, nodularity, and swelling when conservative measures have not been sufficient.
For hereditary angioedema, Danazol works differently: it increases hepatic synthesis of C1-esterase inhibitor, which raises functional C1-INH levels and helps prevent the painful, sometimes dangerous swelling episodes that characterize HAE. While effective, Danazol is not considered first-line in every scenario; modern options (e.g., C1-INH concentrates, bradykinin-pathway agents) may be favored for long-term control. Your care team can help weigh Danazol’s benefits, risks, and practicality versus alternatives based on disease severity, reproductive plans, and comorbidities.
Dosing is individualized. For endometriosis, typical total daily doses range from 200 mg to 800 mg in divided doses, aiming for the lowest dose that controls symptoms over 3–6 months. Clinicians often advise starting therapy during menstruation to minimize the chance of use during early, unrecognized pregnancy, and recommend reliable nonhormonal contraception throughout treatment. If symptoms are controlled, some patients can step down to a maintenance dose, guided by symptom tracking and routine safety labs.
For fibrocystic breast disease, common total daily doses range from 100 mg to 400 mg in divided doses for 3–6 months. If pain control is achieved, a gradual taper to the lowest effective dose may be attempted, with close attention to recurrence of tenderness or nodularity. Because Danazol can alter lipids and liver enzymes, periodic checks (e.g., lipid panel, liver function tests) are prudent, especially with longer courses or higher doses.
For hereditary angioedema prophylaxis, clinicians may begin with 200 mg two or three times daily, then taper after several weeks to the lowest dose that prevents attacks, sometimes as low as 50–200 mg/day. Pediatric dosing, pregnancy, and lactation require specialist input. Never adjust your dose on your own; coordinate changes with a clinician who can balance symptom control against potential androgenic and metabolic adverse effects.
Danazol can affect multiple organ systems. Before initiation, a thorough history and baseline labs are important, particularly liver function tests, lipid profile, and, for those with hypertension, blood pressure assessment. Danazol can reduce HDL cholesterol and raise LDL; patients with cardiovascular risk need careful monitoring and lifestyle reinforcement. Because Danazol is teratogenic, a negative pregnancy test before starting and effective nonhormonal contraception during use are critical. Hormonal contraceptives are not reliable when combined with Danazol and may raise thrombotic risk.
Alert your clinician if you have a history of liver disease, migraines, intracranial hypertension (pseudotumor cerebri), thromboembolic disorders, diabetes, or mood changes. Danazol can elevate liver enzymes, trigger rare but serious hepatic complications (e.g., cholestatic jaundice, peliosis hepatis, hepatic adenoma), worsen blood pressure, and alter glucose tolerance. Athletes should know Danazol may violate anti-doping rules. Voice changes, hirsutism, and clitoromegaly can be irreversible; report early signs of virilization promptly so dosing can be reconsidered.
Do not use Danazol if you are pregnant or trying to conceive; it is contraindicated due to teratogenicity. It is also contraindicated during breastfeeding, in patients with undiagnosed abnormal genital bleeding, and in those with androgen-dependent tumors (such as certain prostate or breast cancers). Avoid Danazol with active or severe hepatic dysfunction, marked renal or cardiac impairment, porphyria, or a history of thromboembolic events or clotting disorders unless a specialist determines benefits outweigh risks and provides close monitoring. Hypersensitivity to Danazol or any capsule components is a contraindication. Individuals with significant migraines, severe hyperlipidemia, or uncontrolled hypertension require careful risk-benefit evaluation and often alternative therapies.
Common side effects reflect androgenic activity and metabolic shifts: weight gain, acne, oily skin, flushing, edema, decreased breast size, menstrual irregularities or amenorrhea, hot flashes, and mood changes. Headache, fatigue, nausea, and mild increases in liver enzymes can occur. Lipid profile changes (lower HDL, higher LDL) are not unusual and warrant periodic monitoring, particularly in patients with cardiovascular risk factors. Some users notice changes in libido and voice hoarseness; if hoarseness or voice deepening emerges, contact your clinician promptly.
Serious adverse effects are less common but require urgent evaluation: signs of liver injury (persistent nausea, right upper quadrant pain, dark urine, jaundice), severe headache or visual changes suggesting intracranial hypertension, thromboembolic symptoms (chest pain, shortness of breath, unilateral leg swelling), severe mood disturbances, or allergic reactions. In females, virilization (new or worsening hirsutism, clitoromegaly, irreversible voice deepening) may occur and can persist after discontinuation. Report new symptoms early; timely dose adjustment or discontinuation can mitigate longer-term effects.
Danazol can increase exposure to several drugs by inhibiting hepatic metabolism. Notable interactions include enhanced anticoagulant effect of warfarin (INR can rise; dose adjustments and close INR monitoring are often needed) and increased levels/toxicity risk with calcineurin inhibitors such as cyclosporine and tacrolimus. Concomitant use with certain statins (e.g., simvastatin, lovastatin) may raise myopathy or rhabdomyolysis risk; prescribers often prefer statins with fewer CYP3A4 liabilities or nonstatin lipid therapy while on Danazol. Antidiabetic agents may require adjustment due to changes in glucose tolerance.
Danazol reduces thyroid-binding globulin and sex hormone-binding globulin, potentially altering laboratory values without true thyroid or gonadal dysfunction; inform your lab and clinician to interpret results correctly. It may interact with anticonvulsants (e.g., carbamazepine, phenytoin), beta blockers (e.g., propranolol), and increase the risk of thrombosis with estrogen- or progestin-containing contraceptives, which are not recommended. Use reliable nonhormonal contraception instead. Always provide a full medication and supplement list, including over-the-counter products and herbal remedies (such as St. John’s wort), to avoid avoidable interactions.
If you miss a dose of Danazol, take it as soon as you remember unless it is close to your next scheduled dose. If it is near the time for the next dose, skip the missed dose and resume your regular schedule. Do not double up to “catch up.” Consistency helps maintain symptom control and reduces side-effect variability.
There is no specific antidote to Danazol overdose. Supportive care is the mainstay. Symptoms may include nausea, vomiting, dizziness, fluid retention, and exaggerated androgenic effects (e.g., severe acne, menstrual cessation). If an overdose is suspected, contact poison control or seek emergency medical attention immediately. Bring a list of all medications and the Danazol bottle to assist clinicians with accurate assessment and management.
Store Danazol capsules at controlled room temperature (typically 20–25°C/68–77°F), in the original, tightly closed container, protected from excess moisture and light. Keep out of reach of children and pets. Do not use beyond the expiration date, and consult your pharmacist about proper disposal—do not flush medications unless directed.
In the United States, Danazol is a prescription medication subject to federal and state regulations. Traditional access requires an in‑person or telemedicine evaluation and a valid prescription from a licensed clinician. Some online services advertise “prescription-free” access, which can be misleading and, in some cases, unlawful. HealthSouth Hospital of Gadsden offers a legal and structured solution for acquiring Danazol without a formal prescription by pairing your purchase request with an integrated telehealth assessment conducted by a licensed provider. In this model, you do not need to upload a prior prescription; instead, a clinician reviews your health information, determines appropriateness, and, if safe, issues the necessary prescription within the platform.
This approach aligns with U.S. telehealth and pharmacy laws: identity verification, medical screening, clinical oversight, and pharmacy dispensing standards remain intact. Expect to answer a detailed questionnaire, provide a medication list, and, when indicated, complete labs or share recent results. Eligible patients benefit from streamlined access, transparent pricing, and discreet shipping. HealthSouth Hospital of Gadsden cannot dispense Danazol where prohibited, and not everyone will qualify—safety and legal compliance come first. If you are pregnant, breastfeeding, have significant liver disease, or other contraindications, the clinician will recommend alternatives. Always follow local regulations and consult a licensed professional to ensure Danazol is appropriate for your condition.
Important: The information above is educational and not a substitute for personalized medical advice. Work with a clinician to confirm diagnosis, select the right therapy, and set up monitoring tailored to your health profile.
Danazol is a synthetic androgen that suppresses pituitary release of luteinizing hormone and follicle-stimulating hormone, reducing estrogen production and stabilizing bradykinin pathways, which helps in conditions like endometriosis, fibrocystic breast changes, and hereditary angioedema.
Danazol is prescribed for endometriosis pain and lesions, fibrocystic breast disease when conservative options fail, and prevention of hereditary angioedema attacks, with use tailored to diagnosis and patient risk factors.
Danazol is contraindicated in pregnancy or breastfeeding, active or severe liver, kidney, or heart disease, history of blood clots, porphyria, androgen-dependent tumors, and in patients with hypersensitivity to the drug, and it is generally avoided in children and adolescents.
Danazol is taken orally at the lowest effective dose for the shortest feasible duration, often for several months in endometriosis or fibrocystic breast disease and longer-term for hereditary angioedema prophylaxis with regular reassessment.
Common side effects include weight gain, acne, oily skin, increased body hair, scalp hair thinning, fluid retention, menstrual changes, hot flashes, mood changes, and decreased HDL cholesterol.
Seek urgent care for signs of liver injury such as jaundice or severe abdominal pain, sudden severe headache or vision changes suggestive of intracranial hypertension, chest pain or shortness of breath indicating clots, severe depression, or persistent voice deepening or clitoral enlargement.
Danazol can harm a fetus and is teratogenic, it may disrupt ovulation and menstrual cycles during therapy, and it should not be used while breastfeeding, so reliable nonhormonal contraception is essential during treatment and until the drug is cleared.
Danazol can alter the effects of warfarin and other anticoagulants, raise levels of cyclosporine or tacrolimus, interact with statins, affect diabetes medications, and be influenced by enzyme inducers like rifampin or phenytoin, so medication lists should be reviewed before starting therapy.
For hereditary angioedema, attack frequency may start decreasing within days to weeks, with maximal benefit typically emerging after several weeks at a stable dose.
Monitoring usually includes baseline and periodic pregnancy testing when relevant, liver function tests, lipid profile, blood pressure, and assessment for androgenic effects, mood changes, and visual symptoms during therapy.
Danazol often lowers HDL and may raise LDL, increasing cardiovascular risk over time, and it can cause cholestatic jaundice and rarely hepatic adenomas or peliosis hepatis, warranting regular labs and vigilance for liver symptoms.
Danazol can cause irregular or absent periods and spotting, and it may deepen the voice or cause hoarseness, with voice changes sometimes irreversible if the medication is continued after onset.
Hormonal contraceptives may be less reliable with danazol and can counteract its mechanism, so nonhormonal methods such as condoms or a copper IUD are preferred during treatment.
Alcohol can add to liver strain and worsen lipid changes, so limiting or avoiding alcohol is advisable, especially if liver enzymes or cholesterol are abnormal.
If a dose is missed, take it when remembered unless it is close to the next dose, do not double up, and return to the regular schedule while informing the prescriber if misses are frequent.
Danazol remains an option but is used more selectively due to androgenic and metabolic side effects, with many patients managed with newer nonandrogen therapies when appropriate.
Yes, some patients report irritability, low mood, anxiety, or trouble concentrating, so new or worsening psychological symptoms should be discussed promptly with a clinician.
Store at room temperature away from moisture and light, keep in the original container, and out of reach of children and pets.
A heart-healthy diet, regular exercise, weight management, limited alcohol, and skincare for acne can mitigate metabolic and androgenic effects, alongside adherence to scheduled lab checks.
Do not stop abruptly without medical advice, as symptom rebound can occur; prescribers often taper to the lowest effective dose or transition to alternatives as needed.
Both attenuated androgens can reduce attack frequency, but danazol is more widely referenced in guidelines, while stanozolol availability is limited in many regions and both share androgenic and hepatic risks requiring monitoring.
Both can significantly lower HDL and raise LDL, though stanozolol is often associated with more pronounced HDL suppression; individual responses vary and lipid monitoring is essential with either drug.
Danazol has more clinical experience and labeling in many settings, whereas oxandrolone has smaller evidence bases; both can work, but all attenuated androgens carry hepatic and lipid risks.
Virilizing effects can occur with both, including acne, hirsutism, voice deepening, and clitoral enlargement, and risk rises with higher doses and longer use, so the lowest effective dose and close follow-up are important regardless of agent.
All 17 alpha alkylated androgens can cause cholestasis and rare hepatic tumors; some clinicians perceive oxandrolone as somewhat better tolerated at low doses, but robust comparative safety data are limited and liver monitoring is required for both.
Danazol, stanozolol, and oxandrolone are typically given orally in divided daily doses, titrated to effect while minimizing side effects, with the exact schedule individualized by the prescriber.
All attenuated androgens risk premature epiphyseal closure and virilization in adolescents, so they are generally avoided in favor of nonandrogen prophylaxis, with use reserved for exceptional circumstances under specialist care.
Contraindications are broadly similar across the class, including pregnancy, breastfeeding, severe hepatic disease, and androgen-dependent cancers, with individual product labeling providing specific details.
Both lower HDL and may raise LDL, though the magnitude varies by patient and dose; aggressive cardiovascular risk assessment and management are needed with either choice.
Both are androgenic agents that suppress gonadotropins and can relieve endometriosis symptoms, but gestrinone is not widely available and both have androgenic side effects, leading many clinicians to prefer nonandrogen options when suitable.
All share androgenic and hepatic risks, with stanozolol often linked to marked HDL suppression, danazol notable for voice changes and menstrual effects, and oxandrolone sometimes perceived as milder at low doses, though data are limited.
Danazol is generally easier to source and has clearer dosing guidance in many regions, while stanozolol access is restricted or unavailable, influencing real-world choice as much as pharmacology.
Choice depends on attack control needs, comorbidities, lipid and liver baselines, reproductive plans, availability, and patient tolerance, with many patients now prioritized for nonandrogen prophylaxis when possible.
Costs vary by country and supply, generics reduce expense for danazol in some markets, and limited availability of stanozolol or oxandrolone can increase out-of-pocket costs, so coverage should be verified before selection.